α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

Youn Seok Choi, Talia Hoory, Archana Monie, Annie Wu, Denise Connolly, Chien-Fu Hung

Research output: Contribution to journalArticle

Abstract

Ovarian cancer is one of the leading causes of death from gynecological cancers in the United States. Conventional therapies are unlikely to control advanced stage ovarian cancers, thus requiring innovative alternative therapies. In the current study, we characterized the therapeutic effect of tumor cell-based vaccines combined with the adjuvant, α-galactosylceramide (α-GalCer) using two different mouse models. Our data suggests that treatment with α-GalCer led to an increase in the IFN-γ serum levels in the presence or absence of irradiated mouse ovarian surface epithelial tumor cells (MOSEC). Furthermore, administration of irradiated MOSEC tumor cells with adjuvant α-GalCer generated significant protective and therapeutic antitumor effects against MOSEC tumors in vaccinated C57BL/6 mice. In addition, immune cells expressing CD4, CD8 or NK1.1 markers were found to be important for the protective antitumor effects generated by irradiated tumor cell-based vaccines combined with adjuvant α-GalCer. We also found that treatment of a spontaneous ovarian cancer murine model, the Müllerian inhibiting substance type II receptor T antigen (TgMISIIR-TAg) transgenic mice with ovarian tumor cell-based vaccines combined with adjuvant α-GalCer led to prolonged survival as well as increased numbers of tumor-specific CD8+ T cells. Therefore, irradiated tumor cell-based vaccines in combination with α-GalCer are capable of breaking immune tolerance and generating significant antitumor effects in two different mouse tumor models. Our study serves as a foundation for future clinical translation.

Original languageEnglish (US)
Pages (from-to)5855-5863
Number of pages9
JournalVaccine
Volume26
Issue number46
DOIs
StatePublished - Oct 29 2008

Fingerprint

Galactosylceramides
Cancer Vaccines
ovarian neoplasms
Therapeutic Uses
protective effect
vaccines
therapeutics
adjuvants
Combined Vaccines
Neoplasms
mice
epithelial cells
neoplasms
Ovarian Neoplasms
animal models
Epithelial Cells
alternative medicine
neoplasm cells
immunosuppression
translation (genetics)

Keywords

  • α-Galactosylceramide
  • Adjuvant
  • MOSEC
  • Ovarian
  • Tumor cell-based vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. / Choi, Youn Seok; Hoory, Talia; Monie, Archana; Wu, Annie; Connolly, Denise; Hung, Chien-Fu.

In: Vaccine, Vol. 26, No. 46, 29.10.2008, p. 5855-5863.

Research output: Contribution to journalArticle

Choi, Youn Seok ; Hoory, Talia ; Monie, Archana ; Wu, Annie ; Connolly, Denise ; Hung, Chien-Fu. / α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. In: Vaccine. 2008 ; Vol. 26, No. 46. pp. 5855-5863.
@article{8193182f2dca4374a468213b79d83d15,
title = "α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors",
abstract = "Ovarian cancer is one of the leading causes of death from gynecological cancers in the United States. Conventional therapies are unlikely to control advanced stage ovarian cancers, thus requiring innovative alternative therapies. In the current study, we characterized the therapeutic effect of tumor cell-based vaccines combined with the adjuvant, α-galactosylceramide (α-GalCer) using two different mouse models. Our data suggests that treatment with α-GalCer led to an increase in the IFN-γ serum levels in the presence or absence of irradiated mouse ovarian surface epithelial tumor cells (MOSEC). Furthermore, administration of irradiated MOSEC tumor cells with adjuvant α-GalCer generated significant protective and therapeutic antitumor effects against MOSEC tumors in vaccinated C57BL/6 mice. In addition, immune cells expressing CD4, CD8 or NK1.1 markers were found to be important for the protective antitumor effects generated by irradiated tumor cell-based vaccines combined with adjuvant α-GalCer. We also found that treatment of a spontaneous ovarian cancer murine model, the M{\"u}llerian inhibiting substance type II receptor T antigen (TgMISIIR-TAg) transgenic mice with ovarian tumor cell-based vaccines combined with adjuvant α-GalCer led to prolonged survival as well as increased numbers of tumor-specific CD8+ T cells. Therefore, irradiated tumor cell-based vaccines in combination with α-GalCer are capable of breaking immune tolerance and generating significant antitumor effects in two different mouse tumor models. Our study serves as a foundation for future clinical translation.",
keywords = "α-Galactosylceramide, Adjuvant, MOSEC, Ovarian, Tumor cell-based vaccines",
author = "Choi, {Youn Seok} and Talia Hoory and Archana Monie and Annie Wu and Denise Connolly and Chien-Fu Hung",
year = "2008",
month = "10",
day = "29",
doi = "10.1016/j.vaccine.2008.08.027",
language = "English (US)",
volume = "26",
pages = "5855--5863",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "46",

}

TY - JOUR

T1 - α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

AU - Choi, Youn Seok

AU - Hoory, Talia

AU - Monie, Archana

AU - Wu, Annie

AU - Connolly, Denise

AU - Hung, Chien-Fu

PY - 2008/10/29

Y1 - 2008/10/29

N2 - Ovarian cancer is one of the leading causes of death from gynecological cancers in the United States. Conventional therapies are unlikely to control advanced stage ovarian cancers, thus requiring innovative alternative therapies. In the current study, we characterized the therapeutic effect of tumor cell-based vaccines combined with the adjuvant, α-galactosylceramide (α-GalCer) using two different mouse models. Our data suggests that treatment with α-GalCer led to an increase in the IFN-γ serum levels in the presence or absence of irradiated mouse ovarian surface epithelial tumor cells (MOSEC). Furthermore, administration of irradiated MOSEC tumor cells with adjuvant α-GalCer generated significant protective and therapeutic antitumor effects against MOSEC tumors in vaccinated C57BL/6 mice. In addition, immune cells expressing CD4, CD8 or NK1.1 markers were found to be important for the protective antitumor effects generated by irradiated tumor cell-based vaccines combined with adjuvant α-GalCer. We also found that treatment of a spontaneous ovarian cancer murine model, the Müllerian inhibiting substance type II receptor T antigen (TgMISIIR-TAg) transgenic mice with ovarian tumor cell-based vaccines combined with adjuvant α-GalCer led to prolonged survival as well as increased numbers of tumor-specific CD8+ T cells. Therefore, irradiated tumor cell-based vaccines in combination with α-GalCer are capable of breaking immune tolerance and generating significant antitumor effects in two different mouse tumor models. Our study serves as a foundation for future clinical translation.

AB - Ovarian cancer is one of the leading causes of death from gynecological cancers in the United States. Conventional therapies are unlikely to control advanced stage ovarian cancers, thus requiring innovative alternative therapies. In the current study, we characterized the therapeutic effect of tumor cell-based vaccines combined with the adjuvant, α-galactosylceramide (α-GalCer) using two different mouse models. Our data suggests that treatment with α-GalCer led to an increase in the IFN-γ serum levels in the presence or absence of irradiated mouse ovarian surface epithelial tumor cells (MOSEC). Furthermore, administration of irradiated MOSEC tumor cells with adjuvant α-GalCer generated significant protective and therapeutic antitumor effects against MOSEC tumors in vaccinated C57BL/6 mice. In addition, immune cells expressing CD4, CD8 or NK1.1 markers were found to be important for the protective antitumor effects generated by irradiated tumor cell-based vaccines combined with adjuvant α-GalCer. We also found that treatment of a spontaneous ovarian cancer murine model, the Müllerian inhibiting substance type II receptor T antigen (TgMISIIR-TAg) transgenic mice with ovarian tumor cell-based vaccines combined with adjuvant α-GalCer led to prolonged survival as well as increased numbers of tumor-specific CD8+ T cells. Therefore, irradiated tumor cell-based vaccines in combination with α-GalCer are capable of breaking immune tolerance and generating significant antitumor effects in two different mouse tumor models. Our study serves as a foundation for future clinical translation.

KW - α-Galactosylceramide

KW - Adjuvant

KW - MOSEC

KW - Ovarian

KW - Tumor cell-based vaccines

UR - http://www.scopus.com/inward/record.url?scp=53449099910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53449099910&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.08.027

DO - 10.1016/j.vaccine.2008.08.027

M3 - Article

C2 - 18771701

AN - SCOPUS:53449099910

VL - 26

SP - 5855

EP - 5863

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 46

ER -